These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 34638370)

  • 21. Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?
    Nica A; Covens A; Parra-Herran C; May T
    Gynecol Oncol; 2020 Sep; 158(3):622-630. PubMed ID: 32561124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study of efficacy and safety of modified adjuvant intraperitoneal chemotherapy regimen in carcinoma ovary.
    Dash P; Goel V; Talwar V; Doval DC; Raina S; Goyal P; Upadhyay A; Patnaik N
    Indian J Cancer; 2016; 53(4):607-611. PubMed ID: 28485363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigating the Impact of Body Mass Index on Intraperitoneal Chemotherapy Outcomes in Ovarian and Fallopian Tube Cancer.
    Davis M; Aviki E; Rauh-Hain JA; Worley M; Berkowitz R; Schorge J; Muto M; Clark Sisodia R; Horowitz N; Del Carmen M
    Int J Gynecol Cancer; 2016 Jul; 26(6):1033-40. PubMed ID: 27206282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival outcomes and toxicity of intraoperative intraperitoneal chemotherapy in advanced epithelial ovarian cancer.
    Yoon JY; Koo YJ; Kim MJ; Kim TJ; Lim KT; Lee KH
    Obstet Gynecol Sci; 2014 Nov; 57(6):484-91. PubMed ID: 25469337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer.
    Kothari R; Nagel C; Koopmeiners JS; Ivy JJ; Geller M; Salani R; Argenta PA
    Gynecol Oncol; 2010 Dec; 119(3):491-5. PubMed ID: 20888625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study.
    Unal OU; Yilmaz AU; Yavuzsen T; Akman T; Ellidokuz H
    Asian Pac J Cancer Prev; 2014; 15(15):6165-9. PubMed ID: 25124592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicities, complications, and clinical encounters during intraperitoneal chemotherapy in 17 women with ovarian cancer.
    Sun V; Otis-Green S; Morgan R; Wakabayashi M; Hakim A; Callado ME; Yang E; Ferrell B; Grant M
    Eur J Oncol Nurs; 2013 Jun; 17(3):375-80. PubMed ID: 23153453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.
    Mueller JJ; Kelly A; Zhou Q; Iasonos A; Long Roche K; Sonoda Y; O'Cearbhaill RE; Zivanovic O; Chi DS; Gardner GJ
    Gynecol Oncol; 2016 Dec; 143(3):496-503. PubMed ID: 27692668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Weekly induction intraperitoneal chemotherapy after primary surgical cytoreduction in patients with advanced epithelial ovarian cancer.
    Yu Zang R; Li ZT; Tang J; Huang X; Mo Cai S
    World J Surg Oncol; 2006 Jan; 4():4. PubMed ID: 16423287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer.
    Suidan RS; St Clair CM; Lee SJ; Barlin JN; Long Roche KC; Tanner EJ; Sonoda Y; Barakat RR; Zivanovic O; Chi DS
    Gynecol Oncol; 2014 Sep; 134(3):468-72. PubMed ID: 25042672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intraperitoneal chemotherapy for ovarian cancer: where are we now?
    Singhal P; Lele S
    J Natl Compr Canc Netw; 2006 Oct; 4(9):941-6. PubMed ID: 17020670
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors affecting the completion of intraperitoneal chemotherapy in women with ovarian cancer.
    Robinson WR; Beyer J
    Int J Gynecol Cancer; 2010 Jan; 20(1):70-4. PubMed ID: 20130505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
    Bixel K; Vetter M; Davidson B; Berchuck A; Cohn D; Copeland L; Fowler JM; Havrilesky L; Lee PS; O'Malley DM; Salani R; Valea F; Alvarez Secord A; Backes F
    Gynecol Oncol; 2020 Mar; 156(3):530-534. PubMed ID: 31937450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer.
    Zeimet AG; Reimer D; Radl AC; Reinthaller A; Schauer C; Petru E; Concin N; Braun S; Marth C
    Anticancer Res; 2009 Jul; 29(7):2803-8. PubMed ID: 19596965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer.
    Taylor SE; Petschauer JS; Donovan H; Schorzman A; Razo J; Zamboni WC; Edwards RP; Zorn KK
    Int J Gynecol Cancer; 2019 Jan; 29(1):147-152. PubMed ID: 30640697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin.
    Krasner CN; Castro C; Penson RT; Roche M; Matulonis UA; Morgan MA; Drescher C; Armstrong DK; Wolfe JK; Lee H; Supko JG; Seiden M; Birrer MJ; Dizon DS
    Gynecol Oncol; 2019 May; 153(2):223-229. PubMed ID: 30765148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial.
    Shi T; Jiang R; Yu J; Yang H; Tu D; Dai Z; Shen Y; Zhang Y; Cheng X; Jia H; Tu R; Wang H; Tang J; Luan Y; Cai S; Zang R;
    Br J Cancer; 2018 Jul; 119(1):12-18. PubMed ID: 29899395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraperitoneal access via direct puncture is an alternative way to deliver intraperitoneal chemotherapy in ovarian, fallopian tube and primary peritoneal cancer.
    Lan C; Li Y; Liu J
    Gynecol Oncol; 2009 Jul; 114(1):42-7. PubMed ID: 19398124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma.
    Rettenmaier MA; Micha JP; Bohart R; Goldstein BH
    Eur J Obstet Gynecol Reprod Biol; 2020 Jan; 244():101-105. PubMed ID: 31778904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
    Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
    J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.